Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours

Published:2003-04-30 Issue:6 Volume:30 Page:895-906
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Eriksson David,Joniani Homa Mirzaie,Sheikholvaezin Ali,Löfroth Per-Olov,Johansson Lennart,Riklund Åhlström Katrine,Stigbrand Torgny

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-003-1177-2.pdf

Reference41 articles.

1. Witzig TE. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2001;48 Suppl 1:S91–S95.

2. White CA, Berlfein JR, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2000; 1:303–312.

3. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39:195–201.

4. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med 2001; 28:1725–1735.

5. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259–1266.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerenkov radiation shining a light for cancer theranostics;Nano Today;2024-04

2. Radiation-induced Cell Death and Its Mechanisms;Health Physics;2022-09-06

3. Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial;Radiotherapy and Oncology;2021-02

4. Modulation of DNA Damage Response by Sphingolipid Signaling: An Interplay that Shapes Cell Fate;International Journal of Molecular Sciences;2020-06-24

5. 177Lu-DOTMP induces G2/M cell cycle arrest and apoptosis in MG63 cell line;Journal of Labelled Compounds and Radiopharmaceuticals;2018-07-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3